Ocugen Quote - OCGN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.62

Bid

1.62

Offer

1.64

Volume

2,389,625

1.58 Day's Range 1.66

0.345 52 Week Range 2.105

Market Cap

416.871M

Previous Close

1.63

Open

1.63

Last Trade

1.64

Last Trade Time

09:24:05

Financial Volume

US$ 3,868,528

VWAP

1.6189

Average Volume (3m)

5,671,824

Shares Outstanding

257,328,085

Dividend Yield

PE Ratio

-6.65

Earnings Per Share (EPS)

-0.25

Revenue

6.04M

Net Profit

-63.08M

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal... Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Ortho,prosth,surg Appl,suply

Website

ocugen.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

Ocugen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OCGN. The last closing price for Ocugen was US$1.63. Over the last year, Ocugen shares have traded in a share price range of US$ 0.345 to US$ 2.105.

Ocugen currently has 257,328,085 shares in issue. The market capitalisation of Ocugen is US$419.44 million. Ocugen has a price to earnings ratio (PE ratio) of -6.65.

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering...

Form 8-K - Current report

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE...

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31...

Ocugen to Present at BIO International Convention 2024

MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-0.613496932515	1.63	1.77	1.57	2902969	1.64936436	CS
4	0.09	5.88235294118	1.53	1.979	1.49	4711414	1.74381948	CS
12	0.26	19.1176470588	1.36	2.06	1.15	5671824	1.65720147	CS
26	1.04	179.310344828	0.58	2.105	0.495	7478672	1.42936243	CS
52	1.051	184.710017575	0.569	2.105	0.345	4983401	1.1864608	CS
156	-5.4	-76.9230769231	7.02	17.65	0.345	9005865	4.73192925	CS
260	-1.62	-50	3.24	18.77	0.17	17170664	5.38390221	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VPRVolt Group Ltd	AUD 0.002 (100.00%)	12.5k
KNBOKoonenberry gold Ltd	AUD 0.004 (100.00%)	260.57k
WOAOWide Open Agriculture Ltd	AUD 0.003 (50.00%)	1M
MCTMetalicity Ltd	AUD 0.003 (50.00%)	1.33M
INDIndustrial Minerals Limited	AUD 0.255 (41.67%)	151.45k
ESROBEstrella Resources Limited	AUD 0.001 (-50.00%)	2M
FG1OFlynn Gold Limited	AUD 0.004 (-42.86%)	2.02M
OVTOvanti Ltd	AUD 0.003 (-40.00%)	6.24M
CPOOCulpeo Minerals Ltd	AUD 0.008 (-33.33%)	400k
IMIInfinity Mining Ltd	AUD 0.01 (-28.57%)	232.1k
BGLBellevue Gold Limited	AUD 1.45 (-20.98%)	80.17M
E79E79 Gold Mines Ltd	AUD 0.041 (20.59%)	56.75M
AGYArgosy Minerals Inc	AUD 0.049 (40.00%)	53.8M
JRVJervois Global Ltd	AUD 0.016 (6.67%)	42.87M
REDRed 5 Limited	AUD 0.375 (-5.06%)	36.66M